Ubretid is a potent inhibitor of plasma cholinesterase. Ubretid therefore delays the hydrolysis of suxamethonium and prolongs its action, similar to the effects shown by other anticholinesterase drugs, such as pyridostigmine and donepezil. Ubretid has the potential for the research of urinary retention prolongs the effect of suxamethonium. Ubretid is commonly prescribed for the research of myasthenia gravis and for difficulty in emptying the bladder.
性状
Solid
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
参考文献
[1]. Isono S, et al. Ubretid (distigmine bromide) taken to treat urinary retention prolongs the effect of suxamethonium. J Anesth. 2008;22(3):337.
溶解度数据
In Vitro: DMSO : 100 mg/mL (173.51 mM; Need ultrasonic)配制储备液